Bipartisan AER Bill Requires Reporting For All OTC Drugs, Supplements
This article was originally published in The Tan Sheet
Executive Summary
Manufacturers of nonprescription drugs and dietary supplements will have to provide company contact information on product labels in order for consumers to report serious adverse events associated with the products under long-awaited legislation introduced June 21
You may also be interested in...
AER Bills Likely To See Action In November Lame Duck Session
Both the House and the Senate versions of the Adverse Event Reporting bill may be acted on in the week after November elections, according to the United Natural Products Alliance
Ephedra: Experts Speak Out On The Good, The Bad And The Ugly
Left to its own devices FDA might not conduct a new risk/benefit analysis; however, a citizen petition asking for an analysis of an herb could spur FDA to action, Attorney Marc Ullman told "The Tan Sheet."
CRN Legislative Briefing Addresses Pending Supplement Bills, Needed Policy
A legislative briefing by the Council for Responsible Nutrition concerning dietary supplements provided members of Congress and staff on Capitol Hill with "science-based information" about supplements